Eric M. Reiman

Thermosensory activation of insular cortex

Temperature sensation is regarded as a submodality of touch, but evidence suggests involvement of insular cortex rather than parietal somatosensory cortices. Using positron emission tomography (PET), we found contralateral activity correlated with graded cooling stimuli only in the dorsal margin of the middle/posterior insula in humans. This corresponds to the thermoreceptive- and nociceptive-specific lamina I spinothalamocortical pathway in monkeys, and can be considered an enteroceptive area within limbic sensory cortex. Because lesions at this site can produce the post-stroke central pain syndrome, this finding supports the proposal that central pain results from loss of the normal inhibition of pain by cold. Notably, perceived thermal intensity was well correlated with activation in the right (ipsilateral) anterior insular and orbitofrontal cortices.

Neuroanatomical correlates of pleasant and unpleasant emotion.

Substantial evidence suggests that a key distinction in the classification of human emotion is that between an appetitive motivational system association with positive or pleasant emotion and an aversive motivational system associated with negative or unpleasant emotion. To explore the neural substrates of these two systems, 12 healthy women viewed sets of pictures previously demonstrated to elicit pleasant, unpleasant and neutral emotion, while positron emission tomographic (PET) measurements of regional cerebral blood flow were obtained. Pleasant and unpleasant emotions were each distinguished from neutral emotion conditions by significantly increased cerebral blood flow in the vicinity of the medial prefrontal cortex (Brodmanns area 9), thalamus, hypothalamus and midbrain (P < 0.005). Unpleasant was distinguished from neutral or pleasant emotion by activation of the bilateral occipito-temporal cortex and cerebellum, and left parahippocampal gyrus, hippocampus and amygdala (P < 0.005). Pleasant was also distinguished from neutral but not unpleasant emotion by activation of the head of the left caudate nucleus (P < 0.005). These findings are consistent with those from other recent PET studies of human emotion and demonstrate that there are both common and unique components of the neural networks mediating pleasant and unpleasant emotion in healthy women.

Learning brain connectivity of Alzheimer's disease by sparse inverse covariance estimation

Rapid advances in neuroimaging techniques provide great potentials for study of Alzheimers disease (AD). Existing findings have shown that AD is closely related to alteration in the functional brain network, i.e., the functional connectivity between different brain regions. In this paper, we propose a method based on sparse inverse covariance estimation (SICE) to identify functional brain connectivity networks from PET data. Our method is able to identify both the connectivity network structure and strength for a large number of brain regions with small sample sizes. We apply the proposed method to the PET data of AD, mild cognitive impairment (MCI), and normal control (NC) subjects. Compared with NC, AD shows decrease in the amount of inter-region functional connectivity within the temporal lobe especially between the area around hippocampus and other regions and increase in the amount of connectivity within the frontal lobe as well as between the parietal and occipital lobes. Also, AD shows weaker between-lobe connectivity than within-lobe connectivity and weaker between-hemisphere connectivity, compared with NC. In addition to being a method for knowledge discovery about AD, the proposed SICE method can also be used for classifying new subjects, which makes it a suitable approach for novel connectivity-based AD biomarker identification. Our experiments show that the best sensitivity and specificity our method can achieve in AD vs. NC classification are 88% and 88%, respectively.

Alzheimer's disease: Attack on amyloid-β protein

An antibody therapy markedly reduces aggregates of amyloid-β, the hallmark protein of Alzheimers disease, and might slow cognitive decline in patients. Confirmation of a cognitive benefit would be a game-changer. See Article p.50 Aducanumab is a recombinant human monoclonal antibody that selectively targets the amyloid-β (Aβ) peptide aggregates thought to play a part in the neurodegenerative process in Alzheimers disease. Several Alzheimers disease drugs have failed in development in recent years — including other anti-amyloid antibodies — so there is intense interest in any new developments. A new study reports interim results from a clinical trial of monthly infusions of aducanumab in subjects with prodromal or mild Alzheimers disease. Treatment with aducanumab reduced brain Aβ plaques, an action accompanied by a dose-dependent slowing of clinical decline. The trial data support further development of aducanumab as an Aβ-removing therapy.

Accelerating drug development for Alzheimer's disease through the use of data standards

The exceedingly high rate of failed trials in Alzheimers disease (AD) calls for immediate attention to improve efficiencies and learning from past, ongoing, and future trials. Accurate, highly rigorous standardized data are at the core of meaningful scientific research. Data standards allow for proper integration of clinical data sets and represent the essential foundation for regulatory endorsement of drug development tools. Such tools increase the potential for success and accuracy of trial results.